Our findings not only validated the markers that predict the clinical prognosis of HER2+ BC from the perspective of exosomes, but also provide a research foundation for establishing the link between exosome signatures and the immunological microenvironment in HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.